Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

@article{Fletcher2000PharmacologicCO,
  title={Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.},
  author={Courtney V Fletcher and Richard C Brundage and Rory P. Remmel and Linda M Page and Dennis R. Weller and Nancy R. Calles and Cara Simon and Mark W. Kline},
  journal={Antimicrobial agents and chemotherapy},
  year={2000},
  volume={44 4},
  pages={1029-34}
}
The use of human immunodeficiency virus (HIV) protease inhibitors in children has lagged behind that in adults because of the lack of suitable pediatric formulations and information on safe and effective dosing regimens. This study was designed to obtain pharmacokinetic information on indinavir, administered to HIV-infected children also receiving therapy with two nucleoside agents, and to explore relationships between pharmacokinetic parameters and anti-HIV effect. Indinavir was initiated at a… CONTINUE READING